Background/Aims: This study was conducted to evaluate the clinicopathologic characteristics and surgical outcome of perforated or bleeding gastric cancer patients. Methods: Twenty-six gastric cancer patients undergoing emergency surgery for free peroration (n = 13) or severe bleeding (n = 13) were reviewed. Results: In the perforation group, tumors were mainly located in the greater curvature and anterior wall, but in the bleeding group, they were mainly in the lesser curvature. Three (23%) patients in the perforation group and 7 (54%) in the bleeding group received potentially curative resections (p = 0.11). The postoperative morbidity rate and mortality rate were 31 (8/26) and 8% (2/26), respectively. Median survival time after operation was 5.5 months. One patient in the perforation group and 3 patients in the bleeding group who underwent curative resection survived more than 30 months without recurrence. Three factors were found to be associated with improved survival after emergency surgery: potentially curative resection; TNM stage, and the absence of postoperative complications. Conclusion: Emergency surgery for gastric cancer patients with perforation or severe bleeding is associated with a low curative resection rate and a high postoperative complication rate. However, long-term survival can be expected in those patients who underwent curative resection with earlier stage gastric cancer.

Keywords:
Gastric cancer, Perforation, Bleeding, Emergency surgery
1.
Stechenberg L, Bunch RH, Anderson MC: The surgical therapy for perforated gastric cancer. Am Surg 1981;47:208–210.
2.
Moreno-Otero R, Rodriguez S, Carbo J, Mearin F, Pajares JM: Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma. J Surg Oncol 1987;36:130–133.
3.
Gertsch P, Yip SK, Chow LW, Lauder IJ: Free perforation of gastric carcinoma. Results of surgical treatment. Arch Surg 1995;130:177–181.
4.
Lehnert T, Buhl K, Dueck M, Hinz U, Herfarth C: Two-stage radical gastrectomy for perforated gastric cancer. Eur J Surg Oncol 2000;26:780–784.
5.
Adachi Y, Mori M, Maehara Y, Matsumata T, Okudaira Y, Sugimachi K: Surgical results of perforated gastric carcinoma: an analysis of 155 Japanese patients. Am J Gastroenterol 1997;92:516–518.
6.
Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T: Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol 2002;80:181–185.
7.
Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ: Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 1997;84:1731–1736.
8.
Alvarez JA, Baldonedo RF, Bear IG, Truan N, Pire G, Alvarez P: Obstructing colorectal carcinoma: outcome and risk factors for morbidity and mortality. Dig Surg 2005;22:174–181.
9.
Central Cancer Registry of Korea: Annual Report of the Central Cancer Registry in Korea. Seoul, Ministry of Health and Welfare, 2002.
10.
So JB, Yam A, Cheah WK, Kum CK, Goh PM: Risk factors related to operative mortality and morbidity in patients undergoing emergency gastrectomy. Br J Surg 2000;87:1702–1707.
11.
Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K: Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767–2773.
12.
Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ: Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099–1102.
13.
Sobin LH, Wittekind CH: TNM Classification of Malignant Tumors, ed 5. International Union Against Cancer (UICC). New York, Wiley, 1997.
14.
Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K: Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 2000;83:986–991.
15.
Korea Gastric Cancer Association: Nationwide Gastric Cancer Report in Korea. J Korean Gastric Cancer Assoc 2002;2:105–114.
16.
Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T: Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg 2002;68:434–440.
17.
Pereira J, Phan T: Management of bleeding in patients with advanced cancer. Oncologist 2004;9:561–570.
18.
A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992;65:934–941.
19.
Biswal BM, Lal P, Rath GK, Mohanti BK: Hemostatic radiotherapy in carcinoma of the uterine cervix. Int J Gynaecol Obstet 1995;50:281–285.
20.
Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF: Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 2006;243:189–195.
21.
Adachi Y, Aramaki M, Shiraishi N, Shimoda K, Yasuda K, Kitano S: Long-term survival after perforation of advanced gastric cancer: case report and review of the literature. Gastric Cancer 1998;1:80–83.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.